Vontobel Holding Ltd. Sells 686 Shares of Stryker Corporation $SYK

Vontobel Holding Ltd. decreased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,122 shares of the medical technology company's stock after selling 686 shares during the quarter. Vontobel Holding Ltd.'s holdings in Stryker were worth $9,543,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of SYK. Brighton Jones LLC grew its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares in the last quarter. Harbor Capital Advisors Inc. bought a new position in Stryker in the first quarter worth approximately $1,840,000. GAMMA Investing LLC grew its stake in Stryker by 16.4% in the first quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company's stock worth $2,075,000 after purchasing an additional 785 shares in the last quarter. Integrated Advisors Network LLC grew its stake in Stryker by 10.7% in the first quarter. Integrated Advisors Network LLC now owns 3,781 shares of the medical technology company's stock worth $1,407,000 after purchasing an additional 366 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Stryker by 1.1% in the first quarter. Assenagon Asset Management S.A. now owns 10,375 shares of the medical technology company's stock worth $3,862,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on SYK. Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Finally, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Stryker in a research report on Wednesday. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Stock Performance

Shares of SYK opened at $370.21 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a fifty day moving average price of $380.53 and a 200-day moving average price of $378.80. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a market cap of $141.53 billion, a PE ratio of 49.03, a P/E/G ratio of 2.70 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the prior year, the business posted $2.81 EPS. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is 44.50%.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of the firm's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.